227 related articles for article (PubMed ID: 28403964)
1. [Can new molecular profiles in epithelial ovarian cancer modify therapeutics?].
Lavoué V; Rousselin A; Delplanque S; Pinsard M; Henno S; Foucher F; Levêque J; de la Motte Rouge T
J Gynecol Obstet Hum Reprod; 2017 Feb; 46(2):107-112. PubMed ID: 28403964
[TBL] [Abstract][Full Text] [Related]
2. The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer.
Dion L; Carton I; Jaillard S; Nyangoh Timoh K; Henno S; Sardain H; Foucher F; Levêque J; de la Motte Rouge T; Brousse S; Lavoué V
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32679669
[TBL] [Abstract][Full Text] [Related]
3. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
4. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
5. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
6. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
7. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
Konstantinopoulos PA; Spentzos D; Karlan BY; Taniguchi T; Fountzilas E; Francoeur N; Levine DA; Cannistra SA
J Clin Oncol; 2010 Aug; 28(22):3555-61. PubMed ID: 20547991
[TBL] [Abstract][Full Text] [Related]
9. Drug-Resistant Epithelial Ovarian Cancer: Current and Future Perspectives.
Mehrotra M; Phadte P; Shenoy P; Chakraborty S; Gupta S; Ray P
Adv Exp Med Biol; 2024; 1452():65-96. PubMed ID: 38805125
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic histologique et moléculaire des cancers de l'ovaire - recommandations pour la pratique clinique Saint-Paul 2021: Histological and molecular diagnosis of ovarian.
Genestie C; Gladieff L; Frère-Belda ML; Lortholary A; Vaur D; Treilleux I; Lyonnet DS
Bull Cancer; 2021 Dec; 108(9S1):S33-S38. PubMed ID: 34955160
[TBL] [Abstract][Full Text] [Related]
11. [Epithelial ovarian cancer and fertility preservation: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
Uzan C; Courbiere B; Chabbert-Buffet N
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):180-186. PubMed ID: 30704956
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.
Lee YK; Park NH; Lee H
Exp Mol Med; 2015 Nov; 47(11):e195. PubMed ID: 26584681
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
[No Abstract] [Full Text] [Related]
14. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
Le Page C; Rahimi K; Köbel M; Tonin PN; Meunier L; Portelance L; Bernard M; Nelson BH; Bernardini MQ; Bartlett JMS; Bachvarov D; Gotlieb WH; Gilks B; McAlpine JN; Nachtigal MW; Piché A; Watson PH; Vanderhyden B; Huntsman DG; Provencher DM; Mes-Masson AM
BMC Cancer; 2018 Mar; 18(1):347. PubMed ID: 29587661
[TBL] [Abstract][Full Text] [Related]
16. [Management of hereditary ovarian cancer].
Joó JG; Ládi S; Nagy BZ; Langmár Z
Orv Hetil; 2011 Oct; 152(40):1596-608. PubMed ID: 21945869
[TBL] [Abstract][Full Text] [Related]
17. Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
Vanderstichele A; Busschaert P; Olbrecht S; Lambrechts D; Vergote I
Eur J Cancer; 2017 Nov; 86():5-14. PubMed ID: 28950147
[TBL] [Abstract][Full Text] [Related]
18. Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
Zhang M; Liu G; Xue F; Edwards R; Sood AK; Zhang W; Yang D
Gynecol Oncol; 2016 Apr; 141(1):57-64. PubMed ID: 27016230
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
Artioli G; Giannone G; Valabrega G; Maggiorotto F; Genta S; Pignata S; Lorusso D; Cormio G; Scalone S; Nicoletto MO; Greco F; Rossi E; Spagnoletti I; De Giorgi U; Orditura M; Mosconi AM; Kardhashi A; Bogliolo S; Borgato L
Gynecol Oncol; 2021 Jun; 161(3):755-761. PubMed ID: 33888336
[TBL] [Abstract][Full Text] [Related]
20. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
Škapa P; Dundr P
Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]